Ryan Potts
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ryan Potts has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Harold Kim
Department of Medicine, McMaster University, Hamilton, Canada
5 shared publications - Immaculate Fp Nevis
Goodman School of Business, Brock University, St. Catharines, Canada
5 shared publications - Laura Kim
Faculty of Medicine, University British Columbia, Vancouver, Canada
5 shared publications - Arunmozhi Dominic
Department of Medicine, McMaster University, Hamilton, ON Canada
4 shared publications - Gina Tsai
Department of Medicine, Western University, London, Canada
4 shared publications - Jack Chiu
Department of Medicine, Western University, London, Canada
4 shared publications
Latest Publications
- Open Access
- 7 July 2017
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 13 (1) , 33
Erratum to: Do epinephrine auto-injectors have an unsuitable needle length in children and adolescents at risk for anaphylaxis from food allergy?
[This corrects the article DOI: 10.1186/s13223-016-0110-8.].
- 7 July 2017
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 13 (1) , 33
Open AccessErratum to: Do epinephrine auto-injectors have an unsuitable needle length in children and adolescents at risk for anaphylaxis from food allergy?
[This corrects the article DOI: 10.1186/s13223-016-0110-8.].
- Open Access
- 6 March 2016
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 12 (1) , 11
Do epinephrine auto-injectors have an unsuitable needle length in children and adolescents at risk for anaphylaxis from food allergy?
Food allergy is the most common cause of anaphylaxis in children. Intramuscular delivery of epinephrine auto-injectors (EAI) is the standard of care for the treatment of anaphylaxis. We examined if children and adolescents at risk of anaphylaxis weighing 15–30 kg and >30 kg would receive epinephrine into the intramuscular space with the currently available EAI in North America and Europe. The distance from skin to muscle (STMD) and skin to bone (STBD) on the mid third anterolateral area of the right thigh was measured by ultrasound applying either high pressure (max) or slight pressure (min) in 102 children weighing 15–30 kg (group 1) and 100 children and adolescents, weighing more than 30 kg (group 2). Using a high pressure EAI (HPEAI), Epipen Jr® and Auvi-Q®/Allerject® 0.15 mg, 11/102 (11 %) children in group 1 and 38/102 (38 %) using another HPEAI, Jext®, had a STMDmax that showed a risk of intraosseous injection. There was a 1 % risk of subcutaneous injection with these devices. There was no risk of intraosseous injection using a low pressure EAI (LPEAI), Emerade®. In group 2, the risk of intraosseous injection using a HPEAI was 3 % and no risk using a LPEAI. However, the risk of subcutaneous injection using HPEAI was 9 % and using LPEAI was 2 %. There is a risk of intraosseous injection using HPEAI (Epipen®/Epipen Jr®, Auvi-Q®/Allerject® and especially Jext®) in children at risk of anaphylaxis. There was also a risk of subcutaneous injection using the currently available HPEAI in children and adolescents.
- 6 March 2016
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 12 (1) , 11
Open AccessDo epinephrine auto-injectors have an unsuitable needle length in children and adolescents at risk for anaphylaxis from food allergy?
Food allergy is the most common cause of anaphylaxis in children. Intramuscular delivery of epinephrine auto-injectors (EAI) is the standard of care for the treatment of anaphylaxis. We examined if children and adolescents at risk of anaphylaxis weighing 15–30 kg and >30 kg would receive epinephrine into the intramuscular space with the currently available EAI in North America and Europe. The distance from skin to muscle (STMD) and skin to bone (STBD) on the mid third anterolateral area of the right thigh was measured by ultrasound applying either high pressure (max) or slight pressure (min) in 102 children weighing 15–30 kg (group 1) and 100 children and adolescents, weighing more than 30 kg (group 2). Using a high pressure EAI (HPEAI), Epipen Jr® and Auvi-Q®/Allerject® 0.15 mg, 11/102 (11 %) children in group 1 and 38/102 (38 %) using another HPEAI, Jext®, had a STMDmax that showed a risk of intraosseous injection. There was a 1 % risk of subcutaneous injection with these devices. There was no risk of intraosseous injection using a low pressure EAI (LPEAI), Emerade®. In group 2, the risk of intraosseous injection using a HPEAI was 3 % and no risk using a LPEAI. However, the risk of subcutaneous injection using HPEAI was 9 % and using LPEAI was 2 %. There is a risk of intraosseous injection using HPEAI (Epipen®/Epipen Jr®, Auvi-Q®/Allerject® and especially Jext®) in children at risk of anaphylaxis. There was also a risk of subcutaneous injection using the currently available HPEAI in children and adolescents.
- Open Access
- 1 August 2014
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 10 (1) , 40
Children under 15 kg with food allergy may be at risk of having epinephrine auto-injectors administered into bone
The Epipen® Jr and Allerject® 0.15 mg are currently the most commonly prescribed epinephrine auto-injectors (EAIs) for the management of anaphylaxis in pediatric patients in North America and Canada. To ensure rapid absorption, it should be administered intramuscularly into the anterolateral aspect of the thigh. We examined whether the 12.7-mm needle length of the Epipen® Jr and Allerject® 0.15 mg is adequate for delivering epinephrine intramuscularly in pediatric patients who weighed <15 kg.
- 1 August 2014
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 10 (1) , 40
Open AccessChildren under 15 kg with food allergy may be at risk of having epinephrine auto-injectors administered into bone
The Epipen® Jr and Allerject® 0.15 mg are currently the most commonly prescribed epinephrine auto-injectors (EAIs) for the management of anaphylaxis in pediatric patients in North America and Canada. To ensure rapid absorption, it should be administered intramuscularly into the anterolateral aspect of the thigh. We examined whether the 12.7-mm needle length of the Epipen® Jr and Allerject® 0.15 mg is adequate for delivering epinephrine intramuscularly in pediatric patients who weighed <15 kg.
- Open Access
- 22 July 2014
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 10 (1) , 39
Auto-injector needle length may be inadequate to deliver epinephrine intramuscularly in women with confirmed food allergy
Epinephrine auto-injectors are the standard first aid treatment for anaphylaxis. Intramuscular delivery into the anterolateral aspect of the thigh is recommended for optimal onset of action of epinephrine. The most frequently prescribed auto-injector in North America and Canada is the EpiPen®, which has a needle length of 15.2 mm. Currently, it is unknown whether this needle length is adequate for intramuscular delivery of epinephrine in adult patients at risk of anaphylaxis.
- 22 July 2014
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 10 (1) , 39
Open AccessAuto-injector needle length may be inadequate to deliver epinephrine intramuscularly in women with confirmed food allergy
Epinephrine auto-injectors are the standard first aid treatment for anaphylaxis. Intramuscular delivery into the anterolateral aspect of the thigh is recommended for optimal onset of action of epinephrine. The most frequently prescribed auto-injector in North America and Canada is the EpiPen®, which has a needle length of 15.2 mm. Currently, it is unknown whether this needle length is adequate for intramuscular delivery of epinephrine in adult patients at risk of anaphylaxis.
- Open Access
- 7 May 2014
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 10 (1) , 22
Patients on subcutaneous allergen immunotherapy are at risk of intramuscular injections
Allergen-specific subcutaneous immunotherapy is an effective treatment for certain allergic disorders. Ideally, it should be administered into the subcutaneous space in the mid-posterolateral upper arm. Injections are commonly given using a standard allergy syringe with a needle length of 13 mm. Therefore, there is a risk of intramuscular administration if patients have a skin-to-muscle depth <13 mm, which may increase the risk of anaphylaxis. The objective of this study was to determine whether the needle length of a standard allergy syringe is appropriate for patients receiving subcutaneous immunotherapy.
- 7 May 2014
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 10 (1) , 22
Open AccessPatients on subcutaneous allergen immunotherapy are at risk of intramuscular injections
Allergen-specific subcutaneous immunotherapy is an effective treatment for certain allergic disorders. Ideally, it should be administered into the subcutaneous space in the mid-posterolateral upper arm. Injections are commonly given using a standard allergy syringe with a needle length of 13 mm. Therefore, there is a risk of intramuscular administration if patients have a skin-to-muscle depth <13 mm, which may increase the risk of anaphylaxis. The objective of this study was to determine whether the needle length of a standard allergy syringe is appropriate for patients receiving subcutaneous immunotherapy.